Indication for HDMTX |
|
Non-Hodgkin lymphoma |
41% |
Osteosarcoma |
30% |
Acute lymphoblastic leukemia |
23% |
Other malignancy |
7% |
Median pretreatment MTX concentration |
17μM |
Median time of glucarpidase dose following MTX administration |
3 days |
Total glucarpidase doses |
|
1 dose |
76% |
2 doses |
22% |
3 doses |
2% |
Median reduction in baseline serum MTX after first glucarpidase dose by HPLC (n = 156) |
|
At 15 minutes |
99% |
At 40 hours |
99% |
Adverse events |
|
Paresthesia |
2.0% |
Flushing |
1.8% |
Headache |
1.0% |
HDMTX = high-dose methotrexate; HPLC = high-performance liquid chromatography; MTX= methotrexate [36]